The role of pemetrexed (Alimta®, LY231514) in lung cancer therapy

Clinical Lung Cancer

Volumn 5, Issue 1, 2003, Pages 21-27

  Molina, Julian R ^a   Adjei, Alex A ^a  

^a MAYO CLINIC   (United States)

Author keywords

5 Flourouracil; Folic acid; Multitargeted antifolate; Thymidylate synthase; Vitamin B12

Indexed keywords

CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; DIHYDROFOLATE REDUCTASE; DIHYDROFOLATE REDUCTASE INHIBITOR; DOCETAXEL; FLUOROURACIL; FOLIC ACID; FOLIC ACID ANTAGONIST; GEMCITABINE; LOMETREXOL; NAVELBINE; OXALIPLATIN; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE INHIBITOR; RALTITREXED; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG SAFETY; DYSPNEA; ENZYME INHIBITION; FATIGUE; FOLATE METABOLISM; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MESOTHELIOMA; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; PANCREAS CANCER; RASH; REVIEW; SOLID TUMOR; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; VITAMIN SUPPLEMENTATION;

EID: 0043066790     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2003.n.017     Document Type: Review

References (43)

1. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000; 355:479-485.
2. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997; 15:2996-3018.
3. Shintani Y, Ohta M, Hirabayashi H, et al. New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int J Cancer 2003; 104:790-795.
4. Richards F II, Perry DJ, Goutsou M, et al. Chemotherapy with 5-fluorouracil (5-FU) and cisplatin or 5-FU, cisplatin, and vinblastine for advanced non-small cell lung cancer. A randomized phase II study of the cancer and leukemia group B. Cancer 1991; 67:2974-2979.
5. Ball D, Smith J, Bishop J, et al. A phase III study of radiotherapy with and without continuous-infusion fluorouracil as palliation for non-small-cell lung cancer. Br J Cancer 1997; 75:690-697.
6. Kempin S, Gutierrez J, Wilson E, et al. Raltitrexed (Tomudex): an alternative choice in patients intolerant to 5-fluorouracil. Cancer Invest 2002; 20:992-995.
7. Souhami RL, Rudd RM, Spiro SG, et al. Phase II study of edatrexate in stage III and IV non-small-cell lung cancer. Cancer Chemother Pharmacol 1992; 30:465-468.
8. Lee JS, Libshitz HI, Fossella FV, et al. Improved therapeutic index by leucovorin of edatrexate, cyclophosphamide, and cisptatin regimen for non-small-cell lung cancer. J Natl Cancer Inst 1992; 84:1039-1040.
9. Taylor EC. Design and synthesis of inhibitors of folate-dependent enzymes as antitumor agents. Adv Exp Med Biol 1993; 338:387-408.
10. Schultz RM, Patel VF, Worzalla JF, et al. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res 1999; 19:437-443.
11. Goldman ID, Zhao R. Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin Oncol 2002; 29:3-17.
12. Schilsky RL. Antimetabolites. In: Perry MC, ed. The Chemotherapy Source Book. Baltimore, MD: Williams & Wilkins; 1992:301-315.
13. Grem JL. Fluorinated pyrimidines. In: Chabner BA, Collins JM, eds. Cancer Chemotherapy: Principles and Practice. Philadelphia, PA: Lippincott; 1990:180-224.
14. Zhao R, Babani S, Gao F, et al. The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate. Clin Cancer Res 2000; 6:3687-3695.
15. Rhee MS, Ryan TJ, Galivan J. Glutamyl hydrolase and the multitargeted antifolate LY231514. Cancer Chemother Pharmacol 1999; 44:427-432.
16. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[23-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997; 57:1116-1123.
17. Synold TW, Newman EM, Carroll M, et al. Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity. Clin Cancer Res 1998; 4:2349-2355.
18. McDonald AC, Vasey PA, Walling J, et al. Phase I and pharmacokinetic study of LY231514, the multitargeted antifolate, administered by daily × 5 q 21 schedule. Ann Oncol 1996; 7:126.
19. Rinaldi DA, Burris HA, Dorr FA, et al. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 1995; 13:2842-2850.
20. Rinaldi DA, Kuhn JG, Burris HA, et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 1999; 44:372-380.
21. Allen RH, Stabler SP, Savage DG, et al. Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency, FASEB J 1993; 7:1344-1353.
22. Snow CF. Laboratory diagnosis of vitamin B12 and folate deficiency: a guide for the primary care physician. Arch Intern Med 1999; 159:1289-1298.
23. Moran JR, Greene HL. The B vitamins and vitamin C in human nutrition. I. General considerations and 'obligatory' B vitamins. Am J Dis Child 1979; 133:192-199.
24. Niyikiza C, Baker S, Johnson R, et al. MTA (LY231514): Relationship of vitamin metabolite profile, drug exposure, and other patient characteristics to toxicity. Ann Oncol 1998; 9(suppl 4):126.
25. Stabler SP, Lindenbaum J, Savage DG, et al. Elevation of serum cystathionine levels in patients with cobalamin and folate deficiency. Blood 1993; 81:3404-3413.
26. Celio L, Bajetta E, Toffolatti L, et al. Phase II trial of pemetrexed disodium administered every 21 days in patients (pts) with gastric cancer; efficacy and toxicity without and with folic acid. Ann Oncol 2000; 11 (suppl 4):65 (Abstract #284P).
27. Rusthoven JJ, Eisenhauer E, Butts C, et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999; 17:1194-1199.
28. Clarke SJ, Abratt R, Goedhals L, et al. Phase II trial of pemetrexed disodium (ALIMTA, LY23154) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol 2002; 13:737-741.
29. Ihde DC. Chemotherapy of lung cancer. New Engl J Med 1992; 327:1434-1437.
30. Smit EF, Mattson K, Von Pawel J, et al. ALIMTA (R) (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann Oncol 2003; 14:455-460.
31. Hanna NH, Shepherd FA, Rosell R, et al. A phase III study of pemetrexed vs docetaxel in patients with recurrent non-small cell lung cancer (NSCLC) who were previously treated with chemotherapy. Proc Am Soc Clin Oncol 2003; 22:622 (Abstract #2563).
32. Thodtmann R, Depenbrock H, Dumez H, et al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 1999; 17:3009-3016.
33. Misset JL, Gamelin E, Campone M, et al. Pemetrexed/oxaliplatin combination: results of a phase I study in metastatic solid tumors. Proc Am Soc Clin Oncol 2002; 21:107a (Abstract #427).
34. Adjei AA, Erlichman C, Sloan JA, et al. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 2000; 18:1748-1757.
35. Ettinger DS, Monnerat C, Kelly K, et al. Phase II trial of pemetrexed + gemcitabine in patients with advanced non-small cell lung cancer: importance of survival over response. Proc Am Soc Clin Oncol 2002; 21:311a (Abstract #1243).
36. Clarke S, Millward M, Beale P, et al. Phase I trial of pemetrexed disodium and vinorelbine (VNB) in patients with advanced malignancy. Ann Oncol 2000; 11:140 (Abstract #641P).
37. Manegold C, Gatzemeier U, von Pawel J, et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial. Ann Oncol 2000; 11:435-440.
38. Shepherd FA, Dancey J, Arnold A, et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 2001; 92:595-600.
39. Hughes A, Calvert F, Azzabi A, et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 2002; 20:3533-3544.
40. Scagliotti G, Kortsik C, Castellano D, et al. Phase II randomized study of pemetrexed plus carboplatin as front-line chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer. Proc Am Soc Clin Oncol 2003; 22:625 (Abstract #2513).
41. Adjei AA, Erlichman C. A phase I trial of MTA and gemcitabine in patients with locally advanced or metastatic cancer. Semin Oncol 1999; 26(suppl 6):94-98.
42. Tonkinson JL, Worzalla JF, Teng CH, et al. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 1999; 59:3671-3676.
43. Clarke S, Underhill C, White S, et al. Phase II study of pemetrexed and vinorelbine in patients with locally advanced or metastatic non-small cell lung cancer. Ann Oncol 2002; 13(suppl 5): 149 (Abstract #546P).